TIS had agreed with BSI that Device Rule 8 was the most appropriate Rule nearly 18 months ago and this was also the basis under which the MHRA approved the EU clinical trial.
It seems that BSI are now unsure which device rule it should be classified under and have referred the question to the MHRA.
ce mark classification, page-2
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)